[18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer’s disease

Hatashita, Shizuo; Yamasaki, Hidetomo; Suzuki, Yutaka; Tanaka, Kumiko; Wakebe, Daichi; Hayakawa, Hideki

doi:10.1007/s00259-013-2564-y

Cited by 94 publications

(98 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The cortical retention of 18 F-flutemetamol has been compared to 11 C-Pittsburgh compound B ( 11 C-PIB) [9] in clinical populations such as amnestic mild cognitive impairment (aMCI) patients together with clinically probable AD patients [10], or aMCI and clinically probable AD together with healthy controls [11], but not in cohorts consisting exclusively of cognitively intact older adults. This is crucial since the discriminative value of a tracer may also depend on the population under study.…”

Section: F-labeled Tracers Currently Approved By the Food And Drugs Amentioning

confidence: 99%

“…The concordance between two tracers may be better in a mixed sample of patients and controls then in a group consisting exclusively of cognitively normal controls. In cognitively intact older adults ligand retention values may lie closer to threshold than in patients with probable AD and it has been hypothesized that 11 C-PIB could potentially outperform 18 Flabelled tracers under such conditions [12]. Other 18 F-labelled amyloid tracers ( 18 F-florbetaben [7], 18 F-florbetapir [8], 18 F-AZD4694 [13]) have also been compared with 11 C-PIB within subjects, again mostly in clinical patient populations combined with cognitively intact older adults [14,15].…”

Section: F-labeled Tracers Currently Approved By the Food And Drugs Amentioning

confidence: 99%

“…Therefore, the aim of this study was to directly compare 18 F-flutemetamol to 11 C-PIB within the same subjects in a prospective community-recruited cohort of cognitively intact older adults. We evaluated concordance between 18 F-flutemetamol versus 11 C-PIB binary classifications based on semiquantitative assessment and visual reads, as well as the correlations between the semiquantitative measures.…”

Section: F-labeled Tracers Currently Approved By the Food And Drugs Amentioning

confidence: 99%

See 2 more Smart Citations

Amyloid imaging in cognitively normal older adults: comparison between 18F-flutemetamol and 11C-Pittsburgh compound B

Adamczuk

Schaeverbeke

Nelissen

et al. 2015

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose: Preclinical, or asymptomatic, Alzheimer's disease (AD) refers to the presence of positive AD biomarkers in the absence of cognitive deficits. This research concept is being applied to define target populations for clinical drug development. In a prospective communityrecruited cohort of cognitively intact older adults, we compared two amyloid imaging markers within subjects: 18 F-flutemetamol and 11 C-Pittsburgh compound B ( 11 C-PIB). Methods:In 32 community-recruited cognitively intact older adults aged between 65 and 80 years, we determined the concordance between binary classification based on 18 Fflutemetamol versus 11 C-PIB according to semiquantitative assessment (standardized uptake value ratio in composite cortical volume, SUVRcomp) and, alternatively, according to visual reads.We also determined the correlation between 18 F-flutemetamol and 11 C-PIB SUVR and evaluated Correlations in neocortical regions were significantly lower with pons as reference region. PVC improved the correlation in striatum and medial temporal cortex.

show abstract

Section: F-labeled Tracers Currently Approved By the Food And Drugs Amentioning

confidence: 99%

Section: F-labeled Tracers Currently Approved By the Food And Drugs Amentioning

confidence: 99%

Section: F-labeled Tracers Currently Approved By the Food And Drugs Amentioning

confidence: 99%

See 1 more Smart Citation

Amyloid imaging in cognitively normal older adults: comparison between 18F-flutemetamol and 11C-Pittsburgh compound B

Adamczuk

Schaeverbeke

Nelissen

et al. 2015

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“…This finding suggests a larger normal variation in the cerebellar cortical region of interest, and the results of this study would therefore point to the pons as the favored reference region. However, both structures were previously used as reference regions in studies of quantitative accuracy (26,30,31) with good results, suggesting that the graphical definition of the region has an impact. This study found only an insignificantly higher accuracy referencing pons, and even larger and prospective studies would be needed to determine a preference for either structure.…”

Section: Discussionmentioning

confidence: 99%

Visualization and Quantification of 3-Dimensional Stereotactic Surface Projections for ¹⁸F-Flutemetamol PET Using Variable Depth

2016

View full text Add to dashboard Cite

Three-dimensional stereotactic surface projection (3D-SSP) is a widely used method for the analysis of clinical 18 F-FDG brain studies. However, for PET amyloid scans the use of 3D-SSP is challenging because of nonspecific uptake in white matter. Our objective was to implement a method for 3D-SSP quantification and visualization of 18 F-flutemetamol images that avoids extraction of white matter signal. Methods: Triangulated brain surface models were extracted from a T1-weighted MR template image. Using an 18 F-flutemetamol-negative template, a maximum depth for each vertex on the surface models was calculated to avoid extraction of white matter. The method was evaluated using 18 Fflutemetamol images from 2 cohorts. Cohort 1 consisted of 105 healthy volunteers and was used to create a normal database for each reference region. Cohort 2 consisted of 171 subjects including patients with Alzheimer disease and mild cognitive impairment and healthy volunteers. Images were spatially normalized using an adaptive template registration method, and SUV ratio 3D-SSP values were computed using the pons and cerebellar cortex as reference regions. Images from cohort 2 were then compared with the normal database and classified into negatives and positives, based on a calculated z score threshold. The results were compared with consensus visual interpretation results from 5 trained interpreters blinded to clinical data. Results: With the pons as the reference region, the optimal z score threshold was 1.97, resulting in an overall agreement with visual interpretation results in 170 of 171 images (99.42%). With the cerebellar cortex as the reference region, the optimal z score threshold was 2.41, with an overall agreement with visual interpretation in 168 of 171 images (98.25%). Conclusion: Variable-depth 3D-SSP allows computation and visualization of 18 F-flutemetamol 3D-SSP maps, with minimized contribution from white matter signal while retaining sensitivity in detecting gray matter signal.

show abstract

“…A study of 36 patients with AD, 68 patients with MCI, and 62 controls (stratified by age) demonstrated a strong correlation between the 2 compounds (p < 0.001), along with the ability to discriminate patients with clinically diagnosed AD from older healthy controls with a sensitivity and specificity of 97.2 % and 85.3 %, respectively [34]. However, another study demonstrated that there is increased concordance between both biomarkers, depending on the region of interest (ROI) for comparison.…”

Section: [ 18 F]3'-f-pib or Flutemetamolmentioning

confidence: 99%

Amyloid Imaging: Poised for Integration into Medical Practice

Anand

Sabbagh

2017

Neurotherapeutics

View full text Add to dashboard Cite

Amyloid imaging represents a significant advance as an adjunct in the diagnosis of Alzheimer's disease (AD) because it is the first imaging modality that identifies in vivo changes known to be associated with the pathogenesis. Initially, 11 C-PIB was developed, which was the prototype for many 18 F compounds, including florbetapir, florbetaben, and flutemetamol, among others. Despite the high sensitivity and specificity of amyloid imaging, it is not commonly used in clinical practice, mainly because it is not reimbursed under current Center for Medicare and Medicaid Services guidelines in the USA. To guide the field in who would be most appropriate for the utility of amyloid positron emission tomography, current studies are underway [Imaging Dementia Evidence for Amyloid Scanning (IDEAS) Study] that will inform the field on the utilization of amyloid positron emission tomography in clinical practice. With the advent of monoclonal antibodies that specifically target amyloid antibody, there is an interest, possibly a mandate, to screen potential treatment recipients to ensure that they are suitable for treatment. In this review, we summarize progress in the field to date.

show abstract

[18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer’s disease

Abstract: [(18)F]FMM PET imaging detects Aβ deposition in patients along the continuum from normal cognitive status to dementia of AD and discriminates AD patients from HC subjects, similar to [(11)C]PIB PET.

Cited by 94 publications

References 22 publications

Amyloid imaging in cognitively normal older adults: comparison between 18F-flutemetamol and 11C-Pittsburgh compound B

Amyloid imaging in cognitively normal older adults: comparison between 18F-flutemetamol and 11C-Pittsburgh compound B

Visualization and Quantification of 3-Dimensional Stereotactic Surface Projections for ¹⁸F-Flutemetamol PET Using Variable Depth

Amyloid Imaging: Poised for Integration into Medical Practice

Contact Info

Product

Resources

About

[18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer’s disease

Abstract: [(18)F]FMM PET imaging detects Aβ deposition in patients along the continuum from normal cognitive status to dementia of AD and discriminates AD patients from HC subjects, similar to [(11)C]PIB PET.

Cited by 94 publications

References 22 publications

Amyloid imaging in cognitively normal older adults: comparison between 18F-flutemetamol and 11C-Pittsburgh compound B

Amyloid imaging in cognitively normal older adults: comparison between 18F-flutemetamol and 11C-Pittsburgh compound B

Visualization and Quantification of 3-Dimensional Stereotactic Surface Projections for 18F-Flutemetamol PET Using Variable Depth

Amyloid Imaging: Poised for Integration into Medical Practice

Contact Info

Product

Resources

About

Visualization and Quantification of 3-Dimensional Stereotactic Surface Projections for ¹⁸F-Flutemetamol PET Using Variable Depth